Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

German drugmaker Bayer acquired all rights it does not already own in Vitrakvi, a drug against a variety of cancers driven by a rare genetic mutation, from Eli Lilly's Loxo Oncology.